{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T12:42:34Z","timestamp":1791808954906,"version":"4.3.4"},"reference-count":29,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,4,25]],"date-time":"2019-04-25T00:00:00Z","timestamp":1556150400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004328","name":"Genentech","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004328","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007013","name":"F. Hoffmann-La Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007013","id-type":"DOI","asserted-by":"publisher"}]},{"name":"F. Hoffmann-La Roche, Ltd., Basel, Switzerland"},{"DOI":"10.13039\/100007013","name":"F. Hoffmann-La Roche, Ltd","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007013","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Boehringer Ingelheim"},{"DOI":"10.13039\/100004328","name":"Genentech","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004328","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007013","name":"F. Hoffmann-La Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007013","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","resmedjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Respiratory Medicine"],"published-print":{"date-parts":[[2019,7]]},"DOI":"10.1016\/j.rmed.2019.04.016","type":"journal-article","created":{"date-parts":[[2019,4,24]],"date-time":"2019-04-24T11:30:00Z","timestamp":1556105400000},"page":"44-51","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":77,"special_numbering":"C","title":["Pirfenidone in patients with idiopathic pulmonary fibrosis and more advanced lung function impairment"],"prefix":"10.1016","volume":"153","author":[{"given":"Steven D.","family":"Nathan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrich","family":"Costabel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"Albera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9151-4829","authenticated-orcid":false,"given":"J\u00fcrgen","family":"Behr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wim A.","family":"Wuyts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klaus-Uwe","family":"Kirchgaessler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John L.","family":"Stauffer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1733-6403","authenticated-orcid":false,"given":"Elizabeth","family":"Morgenthien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Willis","family":"Chou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan L.","family":"Limb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul W.","family":"Noble","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.rmed.2019.04.016_bib1","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/1750-1172-3-8","article-title":"Idiopathic pulmonary fibrosis","volume":"3","author":"Meltzer","year":"2008","journal-title":"Orphanet J. Rare Dis."},{"issue":"1","key":"10.1016\/j.rmed.2019.04.016_bib2","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1378\/chest.10-2572","article-title":"Long-term course and prognosis of idiopathic pulmonary fibrosis in the new millennium","volume":"140","author":"Nathan","year":"2011","journal-title":"Chest"},{"issue":"6","key":"10.1016\/j.rmed.2019.04.016_bib3","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1164\/rccm.2009-040GL","article-title":"ATS\/ERS\/JRS\/ALAT Committee on Idiopathic Pulmonary Fibrosis, an official ATS\/ERS\/JRS\/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management","volume":"183","author":"Raghu","year":"2011","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"4","key":"10.1016\/j.rmed.2019.04.016_bib4","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1164\/rccm.201006-0894CI","article-title":"Clinical course and prediction of survival in idiopathic pulmonary fibrosis","volume":"183","author":"Ley","year":"2011","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.rmed.2019.04.016_bib5","series-title":"Summary of Product Characteristics - Esbriet (Pirfenidone)","author":"European Medicines Agency","year":"2018"},{"key":"10.1016\/j.rmed.2019.04.016_bib6","series-title":"Summary of Product Characteristics - Ofev (Nintedanib)","author":"European Medicines Agency","year":"2018"},{"key":"10.1016\/j.rmed.2019.04.016_bib7","series-title":"Highlights of Prescribing Information - Esbriet","author":"Food and Drug Administration","year":"2017"},{"key":"10.1016\/j.rmed.2019.04.016_bib8","series-title":"Highlights of Prescribing Information - Ofev","author":"Food and Drug Administration","year":"2018"},{"issue":"1","key":"10.1016\/j.rmed.2019.04.016_bib9","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1183\/13993003.00026-2015","article-title":"Pirfenidone for idiopathic pulmonary fibrosis: analysis of pooled data from three multinational phase 3 trials","volume":"47","author":"Noble","year":"2016","journal-title":"Eur. Respir. J."},{"issue":"22","key":"10.1016\/j.rmed.2019.04.016_bib10","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1056\/NEJMoa1402584","article-title":"INPULSIS Trial Investigators, Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis","volume":"370","author":"Richeldi","year":"2014","journal-title":"N. Engl. J. Med."},{"issue":"22","key":"10.1016\/j.rmed.2019.04.016_bib11","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1056\/NEJMoa1402582","article-title":"ASCEND Study Group, A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis","volume":"370","author":"King","year":"2014","journal-title":"N. Engl. J. Med."},{"issue":"9779","key":"10.1016\/j.rmed.2019.04.016_bib12","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1016\/S0140-6736(11)60405-4","article-title":"CAPACITY Study Group, Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials","volume":"377","author":"Noble","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.rmed.2019.04.016_bib13","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s12890-016-0171-y","article-title":"Qualitative European survey of patients with idiopathic pulmonary fibrosis: patients' perspectives of the disease and treatment","volume":"16","author":"Russell","year":"2016","journal-title":"BMC Pulm. Med."},{"issue":"5","key":"10.1016\/j.rmed.2019.04.016_bib14","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1136\/thoraxjnl-2015-207011","article-title":"Effect of continued treatment with pirfenidone following clinically meaningful declines in forced vital capacity: analysis of data from three phase 3 trials in patients with idiopathic pulmonary fibrosis","volume":"71","author":"Nathan","year":"2016","journal-title":"Thorax"},{"key":"10.1016\/j.rmed.2019.04.016_bib15","first-page":"A5390","article-title":"Effect of pirfenidone on all-cause mortality (ACM) and forced vital capacity (FVC) in idiopathic pulmonary fibrosis (IPF) patients with low FVC and\/or low DLco: analysis of pooled data from ASCEND and CAPACITY","volume":"195","author":"Nathan","year":"2017","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"1","key":"10.1016\/j.rmed.2019.04.016_bib16","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1164\/ajrccm.159.1.9712108","article-title":"Spirometric reference values from a sample of the general U.S. population","volume":"159","author":"Hankinson","year":"1999","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"2","key":"10.1016\/j.rmed.2019.04.016_bib17","first-page":"185","article-title":"Standardized single breath normal values for carbon monoxide diffusing capacity","volume":"123","author":"Crapo","year":"1981","journal-title":"Am. Rev. Respir. Dis."},{"issue":"Suppl 60","key":"10.1016\/j.rmed.2019.04.016_bib18","first-page":"OA1810","article-title":"Annual rate of FVC decline in patients with IPF treated with pirfenidone: pooled analysis from 3 pivotal studies","volume":"48","author":"Noble","year":"2016","journal-title":"Eur. Respir. J."},{"issue":"1","key":"10.1016\/j.rmed.2019.04.016_bib19","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/S2213-2600(16)30326-5","article-title":"Effect of pirfenidone on mortality: pooled analyses and meta-analyses of clinical trials in idiopathic pulmonary fibrosis","volume":"5","author":"Nathan","year":"2017","journal-title":"Lancet Respir. Med."},{"key":"10.1016\/j.rmed.2019.04.016_bib20","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.rmed.2017.08.003","article-title":"The complimentary role of transbronchial lung cryobiopsy and endobronchial ultrasound fine needle aspiration in the diagnosis of sarcoidosis","volume":"131","author":"Aragaki-Nakahodo","year":"2017","journal-title":"Respir. Med."},{"issue":"5","key":"10.1016\/j.rmed.2019.04.016_bib21","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.resinv.2015.06.001","article-title":"All-case post-marketing surveillance of 1371 patients treated with pirfenidone for idiopathic pulmonary fibrosis","volume":"53","author":"Ogura","year":"2015","journal-title":"Respir. Investig."},{"issue":"22","key":"10.1016\/j.rmed.2019.04.016_bib22","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.2169\/internalmedicine.52.8498","article-title":"Efficacy of pirfenidone in patients with advanced-stage idiopathic pulmonary fibrosis","volume":"52","author":"Sakamoto","year":"2013","journal-title":"Intern. Med."},{"issue":"Suppl 60","key":"10.1016\/j.rmed.2019.04.016_bib23","first-page":"OA1813","article-title":"Analysis of patients with idiopathic pulmonary fibrosis (IPF) with percent predicted forced vital capacity (FVC)<50% treated with pirfenidone (PFD) in RECAP","volume":"48","author":"Costabel","year":"2016","journal-title":"Eur. Respir. J."},{"issue":"5","key":"10.1016\/j.rmed.2019.04.016_bib24","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1007\/s00408-016-9912-1","article-title":"First data on efficacy and safety of nintedanib in patients with idiopathic pulmonary fibrosis and forced vital capacity of \u226450 % of predicted value","volume":"194","author":"Wuyts","year":"2016","journal-title":"Lung"},{"issue":"1","key":"10.1016\/j.rmed.2019.04.016_bib25","article-title":"Safety of pirfenidone in patients with idiopathic pulmonary fibrosis: integrated analysis of cumulative data from 5 clinical trials","volume":"3","author":"Lancaster","year":"2016","journal-title":"BMJ Open Respir. Res."},{"key":"10.1016\/j.rmed.2019.04.016_bib26","series-title":"Pirfenidone Post-authorization Safety Registry (PASSPORT) \u2013 Update and Concomitant Use of NAC And\/or Corticosteroids","author":"Maher","year":"2015"},{"issue":"3","key":"10.1016\/j.rmed.2019.04.016_bib27","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1183\/09031936.00185114","article-title":"Global incidence and mortality of idiopathic pulmonary fibrosis: a systematic review","volume":"46","author":"Hutchinson","year":"2015","journal-title":"Eur. Respir. J."},{"issue":"2","key":"10.1016\/j.rmed.2019.04.016_bib28","doi-asserted-by":"crossref","first-page":"1800230","DOI":"10.1183\/13993003.00230-2018","article-title":"Safety of nintedanib added to pirfenidone treatment for idiopathic pulmonary fibrosis","volume":"52","author":"Flaherty","year":"2018","journal-title":"Eur. Respir. J."},{"issue":"3","key":"10.1016\/j.rmed.2019.04.016_bib29","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1164\/rccm.201706-1301OC","article-title":"INJOURNEY trial investigators, nintedanib with add-on pirfenidone in idiopathic pulmonary fibrosis: results of the INJOURNEY trial","volume":"197","author":"Vancheri","year":"2018","journal-title":"Am. J. Respir. Crit. Care Med."}],"container-title":["Respiratory Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0954611119301374?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0954611119301374?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T11:49:20Z","timestamp":1760615360000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0954611119301374"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7]]},"references-count":29,"alternative-id":["S0954611119301374"],"URL":"https:\/\/doi.org\/10.1016\/j.rmed.2019.04.016","relation":{},"ISSN":["0954-6111"],"issn-type":[{"value":"0954-6111","type":"print"}],"subject":[],"published":{"date-parts":[[2019,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pirfenidone in patients with idiopathic pulmonary fibrosis and more advanced lung function impairment","name":"articletitle","label":"Article Title"},{"value":"Respiratory Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rmed.2019.04.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}